<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7989ED9B-5D1A-4201-A8BD-AB943285E55A"><gtr:id>7989ED9B-5D1A-4201-A8BD-AB943285E55A</gtr:id><gtr:name>National Physical Laboratory NPL</gtr:name><gtr:address><gtr:line1>National Physical Laboratory</gtr:line1><gtr:line4>Teddington</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>TW11 0LW</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61B5E6D6-02CE-4BD5-A1E9-773F980F3F74"><gtr:id>61B5E6D6-02CE-4BD5-A1E9-773F980F3F74</gtr:id><gtr:name>Syntaxin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/109020B0-5900-49F7-980F-01DA20C7C0EE"><gtr:id>109020B0-5900-49F7-980F-01DA20C7C0EE</gtr:id><gtr:name>MRC Cell Biology Unit</gtr:name><gtr:address><gtr:line1>University College London</gtr:line1><gtr:line2>Gower Street</gtr:line2><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/109020B0-5900-49F7-980F-01DA20C7C0EE"><gtr:id>109020B0-5900-49F7-980F-01DA20C7C0EE</gtr:id><gtr:name>MRC Cell Biology Unit</gtr:name><gtr:address><gtr:line1>University College London</gtr:line1><gtr:line2>Gower Street</gtr:line2><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7989ED9B-5D1A-4201-A8BD-AB943285E55A"><gtr:id>7989ED9B-5D1A-4201-A8BD-AB943285E55A</gtr:id><gtr:name>National Physical Laboratory NPL</gtr:name><gtr:address><gtr:line1>National Physical Laboratory</gtr:line1><gtr:line4>Teddington</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>TW11 0LW</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61B5E6D6-02CE-4BD5-A1E9-773F980F3F74"><gtr:id>61B5E6D6-02CE-4BD5-A1E9-773F980F3F74</gtr:id><gtr:name>Syntaxin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D4386906-A91F-4210-A919-28E36A687FCD"><gtr:id>D4386906-A91F-4210-A919-28E36A687FCD</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Cutler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122665003"><gtr:id>3935929C-459C-4CEB-8C68-7959B699A8C6</gtr:id><gtr:title>Endothelial cell biology and the initiation of inflammation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122665003</gtr:grantReference><gtr:abstractText>One of the most visible signs of inflammation is the formation of pus. This is the accumulation of white blood cells at sites of injury, where they act to repair damage. To grab the white cells out of the mix of cells in rapidly flowing blood, the cells lining the blood vessels change so that instead of providing a smooth surface which promotes the flow of blood and prevents the formation of clots, they become selectively sticky. This selective stickiness comes from a special set of molecules that the lining endothelial cells express on their surface. The bound white cells accumulate on the surface of the endothelium, and then pass out between the endothelial cells into the tissue where they act. The endothelial cells ability to expose and then retrieve the sticky molecules, the selectins, in a regulated fashion, thus plays a big role in controlling the initiation of inflammation. The team of about half a dozen scientists at the CBU plus collaborators in the UK and abroad are trying to understand the molecular machinery that underpins this process. We study the problem in human cells taken from the lining of umbilical veins which we can grow in the laboratory. By understanding the machinery that controls this process, we hope to learn how to manipulate it so as to gain better control over inflammatory disease.</gtr:abstractText><gtr:technicalSummary>At sites of inflammation, the surface of the endothelial cells lining blood vessels changes to recruit leukocytes. The regulated appearance of a series of molecules which interact with receptors on leukocytes is critical for the initiation of inflammation. The first membrane protein to appear is P-selectin. The disappearance of P-selectin is equally tightly controlled to avoid inappropriately prolonged inflammation. P-selectin is stored within the membrane of the Weibel-Palade body (WPB) within cells so that using regulated exocytosis of the WPBs, it can be placed on the plasma membrane within a few minutes. After its appearance at the cell surface, P-selectin is internalised and 50% then recycles back to WPBs for re-use, while 50% is targeted to the lysosomes for degradation. The functioning of P-selectin thus depends on a series of membrane trafficking events that control its itinerary. Further, the molecular machinery controlling its trafficking integrates P-selectin functioning with the inflammatory state of the cell by responding to physiologically generated signals. We are characterising the machinery controlling the itinerary of P-selectin within primary human endothelial cells obtained from the umbilical cord (HUVECS). We are determining the sequences within P-selectin that target this protein to the WPBs, that control its internalisation in endothelial cells, and that lead to its delivery to lysosomes or to its recycling. We are screening for proteins that interact with these targeting motifs by genetic as well as biochemical methods in addition to employing a candidate approach in identifying key players that control the behaviour of P-selectin. The response of this machinery to inflammatory signalling will be determined. Moreover, in addition to our analyses at the tissue culture level, we are collaborating with colleagues in Sheffield to analyse the effects of defects in the trafficking machinery on the ability of the endothelium to recruit leukocytes using intravital microscopy in mice. P-selectin storage depends on the formation of the WPB, which in turn depend on the haemostatic protein von Willebrands Factor (VWF). We are examining how VWF drives the formation of the WPBs, and in turn how that is affected in Von Willebrands disease- the commonest genetic haemostatic disorder, as well as in other inherited human bleeding disorders. These experiments use siRNA-mediated knock-down of disease genes followed by analyses in vitro using HUVECs of WPB formation and function. Our work on the WPB is revealing which defects in WPB formation might lead to haemostatic problems, and we collaborate with clinical colleagues at Hammersmith and Sheffield in the clinical interpretation of this data.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6853362</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cardiovascular Science</gtr:department><gtr:description>In Vivo functionality</gtr:description><gtr:id>573D5865-40F9-4850-A263-637DF635C216</gtr:id><gtr:impact>Doyle et al, Blood; 2011
Which led to 
Translational work via MRCT, leading to two grants from MRCT and to patent applications etc.</gtr:impact><gtr:outcomeId>iZDdCWSbaPW-1</gtr:outcomeId><gtr:partnerContribution>Endothelial function in vivo</gtr:partnerContribution><gtr:piContribution>Endothelial cell biology in vitro</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>British Heart Foundation Centre of Research Excellence</gtr:department><gtr:description>VWF and Angiogenesis</gtr:description><gtr:id>9D57C3EF-3AE0-444E-8FA3-2559C2828E76</gtr:id><gtr:impact>Papers published:
1. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM (2011) Endothelial von Willebrand factor regulates angiogenesis. Blood 117: 1071-1080
2. Starke RD, Paschalaki KE, Dyer CE, Harrison-Lavoie KJ, Cutler JA, McKinnon TA, Millar CM, Cutler DF, Laffan MA, Randi AM. (2013) Cellular and Molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood. 121: 2773-84

Other publications
10.1136/heartjnl-2011-300920b.39 (2011) BLOOD-DERIVED ENDOTHELIAL PROGENITOR CELLS FROM VON WILLEBRAND\'S DISEASE PATIENTS DEMONSTRATE THAT VON WILLEBRAND FACTOR REGULATES ANGIOGENESIS

000331833601394 (2013) Defective angiopoietin-2 release from von Willebrand disease patients\' blood outgrowth endothelial cells</gtr:impact><gtr:outcomeId>T7RiuKccmjg-1</gtr:outcomeId><gtr:partnerContribution>Expertise and unique reagents plus access to patients</gtr:partnerContribution><gtr:piContribution>Cell Biological expertise</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syntaxin</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>modulating endothelial function</gtr:description><gtr:id>D1070C59-F9D3-46BE-881E-AC7DAC6ED6B1</gtr:id><gtr:impact>We have achieved a significant change in endothelial function, using novel proprietary pharmaceuticals. The company paid for their analysis in our system.</gtr:impact><gtr:outcomeId>E790AFC59F8-1</gtr:outcomeId><gtr:partnerContribution>Unique reagents</gtr:partnerContribution><gtr:piContribution>expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Physical Laboratory</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>super-resolution microscopy</gtr:description><gtr:id>33F80268-1C68-4D68-80D6-8477806BB884</gtr:id><gtr:impact>Paper published in JTH., development of diagnostic methods.
This is a multidisciplinary collaboration, involving physicists, clinicians, and cell biologists.</gtr:impact><gtr:outcomeId>KmFTcE1aZyi-1</gtr:outcomeId><gtr:partnerContribution>Access to a pre-commercial microscope of improved resolution.</gtr:partnerContribution><gtr:piContribution>Cell Biological expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Katharine Dormandy Haemophilia and Thrombosis Centre</gtr:department><gtr:description>super-resolution microscopy</gtr:description><gtr:id>DAD6C851-8F60-4500-818E-0DE408DE8CD0</gtr:id><gtr:impact>Paper published in JTH., development of diagnostic methods.
This is a multidisciplinary collaboration, involving physicists, clinicians, and cell biologists.</gtr:impact><gtr:outcomeId>KmFTcE1aZyi-2</gtr:outcomeId><gtr:partnerContribution>Access to a pre-commercial microscope of improved resolution.</gtr:partnerContribution><gtr:piContribution>Cell Biological expertise</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>core staff briefing</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A96BF84C-AA97-4C78-A075-6967690A3091</gtr:id><gtr:impact>the non-academic core staff of the LMCB attended a non-scientific laypersons version of my research, followed by a long Q&amp;amp;A.

an increase in morale via the increase in understanding of what their work is supporting.</gtr:impact><gtr:outcomeId>sF2XD1kK8Cg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at MRC -Showcase</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4A83B3CD-26F8-4812-BBFB-55E03F7C21C2</gtr:id><gtr:impact>Showcasing our work to UK industry

Unclear, possibly led to interaction with Syntaxin.</gtr:impact><gtr:outcomeId>4F493488BEC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Discussion-  Syntaxin, UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>58454F81-B6BF-4824-AFC5-0524860C1CC1</gtr:id><gtr:impact>hosted discussion with UK biotech company

funding of preliminary experimental work in my lab.</gtr:impact><gtr:outcomeId>A47E23BD439</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development Gap Fund</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>837A4A9F-62EF-47DA-B501-7647E6CABB37</gtr:id><gtr:outcomeId>LTJVz1t4opX</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Development Gap funding</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>36A3C114-C37E-47B7-83C4-8744F8DB7E82</gtr:id><gtr:outcomeId>fxtj5GEhBv10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>identification of CD63 as a potential target for modulation of the inflamatory response of endothelial cells.</gtr:description><gtr:grantRef>MC_U122665003</gtr:grantRef><gtr:id>DFD0EE9D-CF59-4039-AE89-C4075D16B1C5</gtr:id><gtr:impact>DGF funding to my lab.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m9Dw5N7Tgu5</gtr:outcomeId><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Methods of inhibiting inflammation</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>70EE75D7-2364-45A2-BECF-E3A18746F07A</gtr:id><gtr:title>CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d66ce0aaba3696fc6746d777b92fa74b"><gtr:id>d66ce0aaba3696fc6746d777b92fa74b</gtr:id><gtr:otherNames>Doyle EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56a79462a19aa5.30526971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6E3DA49-642F-45A1-9C44-FD2EE11650F9</gtr:id><gtr:title>Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6693be5bcb21b5cbed09267687bf2bf3"><gtr:id>6693be5bcb21b5cbed09267687bf2bf3</gtr:id><gtr:otherNames>Nightingale TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56a79463d3bf54.42476966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>948C8634-FDE5-4807-862A-6B54C4CCE087</gtr:id><gtr:title>Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6693be5bcb21b5cbed09267687bf2bf3"><gtr:id>6693be5bcb21b5cbed09267687bf2bf3</gtr:id><gtr:otherNames>Nightingale TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>56a794627bda45.93953805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04EDAB29-50A7-48A0-B549-6175191C1CEE</gtr:id><gtr:title>A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68eaaf625a2e5f60e0ee5533d489aa3a"><gtr:id>68eaaf625a2e5f60e0ee5533d489aa3a</gtr:id><gtr:otherNames>Kitzm?ller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>41EE184861F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20936ECE-96E7-426D-8B9D-A16DCD4AD966</gtr:id><gtr:title>Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0377188d9a314a9771d6e6deb6606cc"><gtr:id>a0377188d9a314a9771d6e6deb6606cc</gtr:id><gtr:otherNames>Metcalf DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>4FED27E1684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>613427E1-3AD1-4234-8857-44B9FDEFC8C5</gtr:id><gtr:title>Actin coats and rings promote regulated exocytosis.</gtr:title><gtr:parentPublicationTitle>Trends in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6693be5bcb21b5cbed09267687bf2bf3"><gtr:id>6693be5bcb21b5cbed09267687bf2bf3</gtr:id><gtr:otherNames>Nightingale TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0962-8924</gtr:issn><gtr:outcomeId>pm_13573_23_22543050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C754002-6378-41AB-AAAE-B71C8FB3F75C</gtr:id><gtr:title>Nightingale TD, Pattni K, Hume AN, Seabra MC, Cutler DF. Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. Blood. 2009;113(20):5010-5018.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26cdeb1ab863a420e44d6da8a1c62fc7"><gtr:id>26cdeb1ab863a420e44d6da8a1c62fc7</gtr:id><gtr:otherNames>Nightingale T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56a7946385a759.35519533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA07B1A5-9DA1-4CE2-909F-55C64C902732</gtr:id><gtr:title>Lysosome-related organelles: driving post-Golgi compartments into specialisation.</gtr:title><gtr:parentPublicationTitle>Current opinion in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/164069ec9c43b0af58433dee16291a06"><gtr:id>164069ec9c43b0af58433dee16291a06</gtr:id><gtr:otherNames>Raposo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0955-0674</gtr:issn><gtr:outcomeId>56a794653a1322.92308992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D90368E-36BA-43DA-9F88-40248EC6DC80</gtr:id><gtr:title>39 Blood-derived endothelial progenitor cells from Von Willebrand's disease patients demonstrate that Von Willebrand factor regulates angiogenesis</gtr:title><gtr:parentPublicationTitle>Heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089e3bc46fae61ff007634fb3ada86ec"><gtr:id>089e3bc46fae61ff007634fb3ada86ec</gtr:id><gtr:otherNames>Starke R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>56a79463029f32.88180068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8522550-E760-4963-A4C2-02FBFD2E9044</gtr:id><gtr:title>Endothelial von Willebrand factor regulates angiogenesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8bb7e7cfa63685603144fb95af08830"><gtr:id>f8bb7e7cfa63685603144fb95af08830</gtr:id><gtr:otherNames>Starke RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56a794635c8a37.26245189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>790510ED-10CC-4CBC-88E7-22DE6AC6D982</gtr:id><gtr:title>Aftiphilin and gamma-synergin are required for secretagogue sensitivity of Weibel-Palade bodies in endothelial cells.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1978820768ee02aec8c5048dd978901e"><gtr:id>1978820768ee02aec8c5048dd978901e</gtr:id><gtr:otherNames>Lui-Roberts WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>3865A078AC2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2E5C89F-EC2C-4C2C-98D7-E18F7E5D2641</gtr:id><gtr:title>High-pressure freezing provides insights into Weibel-Palade body biogenesis.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62ab9995e58650c8789d10b09f0cffd0"><gtr:id>62ab9995e58650c8789d10b09f0cffd0</gtr:id><gtr:otherNames>Zenner HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>56a79464e75539.26471982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E12E56A-F9AC-48EA-B6A7-B2E238AAA47F</gtr:id><gtr:title>Myosin Va acts in concert with Rab27a and MyRIP to regulate acute von-Willebrand factor release from endothelial cells.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffe0b594acdfe8d9e40956f193a7c4cd"><gtr:id>ffe0b594acdfe8d9e40956f193a7c4cd</gtr:id><gtr:otherNames>Rojo Pulido I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>56a7946328b9e6.38696131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BF66B04-E472-4802-9DE0-01FB0EBF6479</gtr:id><gtr:title>Endothelial Von Willebrand factor regulates angiogenesis</gtr:title><gtr:parentPublicationTitle>Vascular Pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089e3bc46fae61ff007634fb3ada86ec"><gtr:id>089e3bc46fae61ff007634fb3ada86ec</gtr:id><gtr:otherNames>Starke R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>56a7946230eb31.96340038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFC76979-ED46-4343-9FDC-DFFBCAE13B96</gtr:id><gtr:title>Formation and function of Weibel-Palade bodies.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0377188d9a314a9771d6e6deb6606cc"><gtr:id>a0377188d9a314a9771d6e6deb6606cc</gtr:id><gtr:otherNames>Metcalf DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>120030CE5A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E0EADFC-F305-407A-BE9F-793F12C4025C</gtr:id><gtr:title>CELLULAR AND MOLECULAR BASIS OF VON WILLEBRAND DISEASE: STUDIES ON BLOOD OUTGROWTH ENDOTHELIAL CELLS</gtr:title><gtr:parentPublicationTitle>ATHEROSCLEROSIS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fd7b81c053e686bf7b1a88a2bd4f26e"><gtr:id>5fd7b81c053e686bf7b1a88a2bd4f26e</gtr:id><gtr:otherNames>Starke R. D.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>56a79462592885.70180030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585E5F01-EB1C-4BA9-8F1B-58B5DA0BEE83</gtr:id><gtr:title>Fishing for platelets.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83b2fff513c6a054d60684d7fe44eb58"><gtr:id>83b2fff513c6a054d60684d7fe44eb58</gtr:id><gtr:otherNames>Cutler DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56a79463af6bc5.26617082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2013420E-7306-4D32-A69D-2597FD764081</gtr:id><gtr:title>Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8bb7e7cfa63685603144fb95af08830"><gtr:id>f8bb7e7cfa63685603144fb95af08830</gtr:id><gtr:otherNames>Starke RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13573_23_23355534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84430D65-36CD-4142-8DAC-4D0BA699E14E</gtr:id><gtr:title>A role for Rab10 in von Willebrand factor release discovered by an AP-1 interactor screen in C. elegans.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/281bcbfd04ee6e1792b2926a25fcc567"><gtr:id>281bcbfd04ee6e1792b2926a25fcc567</gtr:id><gtr:otherNames>Michaux G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>56a79462ccd4e0.10629060</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122665003</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>